Population-based Investigation of Aneurysm Incidence

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06412783

Enrollment

4711

Registered

2024-05-14

Start date

2023-10-01

Completion date

2025-02-28

Last updated

2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysm

Keywords

Intracranial Aneurysms, Screening, Blood test

Brief summary

Most intracranial aneurysms are found accidentally in neurovascular imaging. And these inspection methods are limited by the problems of instrument fixation, radiation, time-consuming, contrast agent toxicity and so on. At present, blood test is an ideal alternative method for early diagnosis. Compared with imaging examination, it is economical, general screening and convenient. Blood test is simple to operate, easy to be accepted by patients, and less invasive. Early screening of aneurysms can be performed.

Interventions

DIAGNOSTIC_TESTblood test

performing blood tests on the participants for specific markers.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 35-75 * Individuals with normal cognitive and communication abilities * No serious complications, such as uncontrolled hypertension, diabetes or other chronic diseases that may affect the test results. * Basic blood test is normal or close to normal range.

Exclusion criteria

* Pregnancy * Severe heart disease, renal insufficiency, liver dysfunction and other major diseases. * In the past 6 months, there were strokes, or other types of intracranial tumors, infections and other diseases that may affect the screening results. * There are metal implants, including dentures, pacemakers, etc. * Using or recently used drugs that may affect blood biomarkers ( such as anticoagulant drugs, immunosuppressive agents, etc. ). * There are serious mental illness or cognitive dysfunction, such as claustrophobia, unable to cooperate with the completion of the test. * It is currently participating in other clinical trials or has participated in other clinical trials in the past 3 months.

Design outcomes

Primary

Measure	Time frame	Description
Specific markers are detected	1hours after blood collection	oleic acid, arachidonic acid, docasa-hexaenoic acid, interleukin 1β， interleukin 1ra, tumor necrosis factors, SOD3, PPIA, S100A8, S100A9, MPO, APOA4, THBS1.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026